

FAST FACTS

NRG CC007CD - INCREASING THE DOSE OF SURVIVORSHIP CARE PLANNING IN PROSTATE CANCER SURVIVORS WHO RECEIVE ANDROGEN DEPRIVATION THERAPY

Patient Eligibility Criteria

1. The participant must be able to complete required questionnaires in English.
2. The participant must have a diagnosis of prostate adenocarcinoma that will be treated with RT plus ADT with curative intent. Both definitive RT (intact prostate) and post-prostatectomy RT patients are eligible.
 - The ADT must be planned for at least 4 months and must include LHRH agonist or LHRH antagonist.
 - ADT may have started for no more than 120 days before registration.
3. The participant must have a primary care provider and/or cardiologist or plan to obtain one per Section 3.2.
4. Comorbidities assessed at study entry using the ACE-27 instrument (located on the CTSU website).
5. Completion and submission of the Brief Health Literacy Screen, Coordination of Care, and Patient Satisfaction with Care within 42 days prior to registration (See Section 11.3).
6. The patient or a legally authorized representative must provide study-specific informed consent prior to study entry.

Patient Screening and Enrollment Process (04-Oct-2019)

